Analysts expect NCI Building Systems, Inc. (NYSE:NCS) to report $0.09 EPS on March, 6.They anticipate $0.04 EPS change or 80.00% from last quarter’s $0.05 EPS. NCS’s profit would be $5.95 million giving it 47.22 P/E if the $0.09 EPS is correct. After having $0.32 EPS previously, NCI Building Systems, Inc.’s analysts see -71.88% EPS growth. The stock decreased 0.29% or $0.05 during the last trading session, reaching $17. About 423,598 shares traded. NCI Building Systems, Inc. (NYSE:NCS) has risen 17.08% since February 19, 2017 and is uptrending. It has outperformed by 0.38% the S&P500.
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $10.54 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.
Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on February, 28. They expect $-1.63 EPS, up 13.30% or $0.25 from last year’s $-1.88 per share. After $-1.73 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts -5.78% EPS growth.
Cormorant Asset Management Llc holds 3.33% of its portfolio in bluebird bio, Inc. for 137,500 shares. Eventide Asset Management Llc owns 412,000 shares or 3.21% of their US portfolio. Moreover, First Light Asset Management Llc has 1.57% invested in the company for 36,085 shares. The Pennsylvania-based Emerald Advisers Inc Pa has invested 1.03% in the stock. Baillie Gifford & Co, a United Kingdom-based fund reported 5.32 million shares.
Ratings analysis reveals 50% of Bluebirdbio’s analysts are positive. Out of 4 Wall Street analysts rating Bluebirdbio, 2 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $80.0 while the high is $87.0. The stock’s average target of $83.50 is -60.86% below today’s ($213.35) share price. BLUE was included in 4 notes of analysts from October 14, 2016. The stock of bluebird bio, Inc. (NASDAQ:BLUE) has “Neutral” rating given on Monday, February 6 by Roth Capital. The rating was downgraded by Cantor Fitzgerald on Friday, October 14 to “Sell”. The rating was maintained by Maxim Group with “Buy” on Thursday, December 1. The firm has “Outperform” rating by Leerink Swann given on Friday, October 14.
The stock increased 2.25% or $4.7 during the last trading session, reaching $213.35. About 645,814 shares traded. bluebird bio, Inc. (BLUE) has risen 112.34% since February 19, 2017 and is uptrending. It has outperformed by 95.64% the S&P500.
Investors sentiment decreased to 1.61 in Q3 2017. Its down 0.11, from 1.72 in 2017Q2. It worsened, as 18 investors sold NCI Building Systems, Inc. shares while 33 reduced holdings. 30 funds opened positions while 52 raised stakes. 60.07 million shares or 2.28% less from 61.47 million shares in 2017Q2 were reported. Goldman Sachs Gp holds 0% of its portfolio in NCI Building Systems, Inc. (NYSE:NCS) for 166,031 shares. D E Shaw & Inc holds 266,175 shares or 0.01% of its portfolio. First Republic Management Inc holds 0.01% or 96,293 shares. Tiaa Cref Inv Management Ltd Liability Company invested 0% in NCI Building Systems, Inc. (NYSE:NCS). Manufacturers Life Ins The accumulated 31,941 shares. 49,488 are held by Zacks Investment Mngmt. California State Teachers Retirement System stated it has 0% in NCI Building Systems, Inc. (NYSE:NCS). 4,300 are owned by Pacad Invest Ltd. Clayton Dubilier & Rice Limited Liability Company reported 30.06 million shares. Ubs Asset Mgmt Americas Inc invested in 627,203 shares or 0.01% of the stock. Fifth Third Bancorporation holds 5,449 shares. Pnc Ser Gp invested in 0% or 2,740 shares. Moneta Grp Invest Ltd Liability Corporation stated it has 20,400 shares or 0.05% of all its holdings. Prudential Financial stated it has 0.01% in NCI Building Systems, Inc. (NYSE:NCS). Thrivent Fincl For Lutherans invested in 0.05% or 946,061 shares.
Since September 12, 2017, it had 0 insider buys, and 7 sales for $141.63 million activity. CD&R Associates VIII – Ltd. sold $138.42 million worth of stock. CHAMBERS NORMAN C also sold $1.66M worth of NCI Building Systems, Inc. (NYSE:NCS) shares. MOORE TODD R also sold $82,500 worth of NCI Building Systems, Inc. (NYSE:NCS) shares. Kuzdal John L sold $384,766 worth of NCI Building Systems, Inc. (NYSE:NCS) on Friday, December 15. 2,750 shares were sold by Little Bradley Scott, worth $53,556.
NCI Building Systems, Inc., together with its subsidiaries, designs, engineers, makes, and markets metal products for the nonresidential construction industry in North America. The company has market cap of $1.12 billion. It operates through three divisions: Engineered Building Systems, Metal Components, and Metal Coil Coating. It has a 22.08 P/E ratio. The Engineered Building Systems segment offers engineered structural members and panels; and self-storage building systems under the Metallic, Mid-West Steel, A & S, All American, Mesco, Star, Ceco, Robertson, Garco, Heritage, and SteelBuilding.com brands to builders, general contractors, developers, and end users directly, as well as through private label companies.